Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06952413

Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

An Exploratory, Placebo-controlled, Double-blind, Phase II Study of the Efficacy and Safety for Rituximab (Genetical Recombination) in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Sponsor: National Center of Neurology and Psychiatry, Japan

Conditions Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Interventions Placebo Rituximab(Genetical Recombination)

Updated 1 time since 2025 Last updated: Apr 23, 2025 Started: Apr 9, 2025 Primary completion: Sep 30, 2026 Completion: Oct 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and is currently actively recruiting participants. National Center of Neurology and Psychiatry, Japan leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

1 version recorded

Recruiting — PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Center of Neurology and Psychiatry, Japan

Data source: National Center of Neurology and Psychiatry, Japan

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kodaira, Japan